BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 12023971)

  • 1. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation.
    Hayashi T; Kaneda T; Toyama Y; Kumegawa M; Hakeda Y
    J Biol Chem; 2002 Aug; 277(31):27880-6. PubMed ID: 12023971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro.
    Fox SW; Haque SJ; Lovibond AC; Chambers TJ
    J Immunol; 2003 Apr; 170(7):3679-87. PubMed ID: 12646633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration.
    Kwak HB; Lee SW; Jin HM; Ha H; Lee SH; Takeshita S; Tanaka S; Kim HM; Kim HH; Lee ZH
    Blood; 2005 Apr; 105(7):2963-9. PubMed ID: 15585657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts.
    Takuma A; Kaneda T; Sato T; Ninomiya S; Kumegawa M; Hakeda Y
    J Biol Chem; 2003 Nov; 278(45):44667-74. PubMed ID: 12944401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
    Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
    Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption.
    Zheng H; Yu X; Collin-Osdoby P; Osdoby P
    J Biol Chem; 2006 Jun; 281(23):15809-20. PubMed ID: 16613848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressors of cytokine signaling-1 and -3 regulate osteoclastogenesis in the presence of inflammatory cytokines.
    Ohishi M; Matsumura Y; Aki D; Mashima R; Taniguchi K; Kobayashi T; Kukita T; Iwamoto Y; Yoshimura A
    J Immunol; 2005 Mar; 174(5):3024-31. PubMed ID: 15728516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor.
    Kaneda T; Nojima T; Nakagawa M; Ogasawara A; Kaneko H; Sato T; Mano H; Kumegawa M; Hakeda Y
    J Immunol; 2000 Oct; 165(8):4254-63. PubMed ID: 11035059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
    Chaisson ML; Branstetter DG; Derry JM; Armstrong AP; Tometsko ME; Takeda K; Akira S; Dougall WC
    J Biol Chem; 2004 Dec; 279(52):54841-8. PubMed ID: 15485831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells.
    Yamada T; Yamazaki H; Yamane T; Yoshino M; Okuyama H; Tsuneto M; Kurino T; Hayashi S; Sakano S
    Blood; 2003 Mar; 101(6):2227-34. PubMed ID: 12411305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells.
    Baetz A; Frey M; Heeg K; Dalpke AH
    J Biol Chem; 2004 Dec; 279(52):54708-15. PubMed ID: 15491991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
    Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
    J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
    Tsujisawa T; Inoue H; Nishihara T
    J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.